Skip to main content

Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.

Publication ,  Journal Article
Li, Y; Cleveland, B; Klots, I; Travis, B; Richardson, BA; Anderson, D; Montefiori, D; Polacino, P; Hu, S-L
Published in: J Virol
January 2008

Glycans on human immunodeficiency virus (HIV) envelope protein play an important role in infection and evasion from host immune responses. To examine the role of specific glycans, we introduced single or multiple mutations into potential N-linked glycosylation sites in hypervariable regions (V1 to V3) of the env gene of HIV type 1 (HIV-1) 89.6. Three mutants tested showed enhanced sensitivity to soluble CD4. Mutant N7 (N197Q) in the carboxy-terminal stem of the V2 loop showed the most pronounced increase in sensitivity to broadly neutralizing antibodies (NtAbs), including those targeting the CD4-binding site (IgG1b12) and the V3 loop (447-52D). This mutant is also sensitive to CD4-induced NtAb 17b in the absence of CD4. Unlike the wild-type (WT) Env, mutant N7 mediates CD4-independent infection in U87-CXCR4 cells. To study the immunogenicity of mutant Env, we immunized pig-tailed macaques with recombinant vaccinia viruses, one expressing SIVmac239 Gag-Pol and the other expressing HIV-1 89.6 Env gp160 in WT or mutant forms. Animals were boosted 14 to 16 months later with simian immunodeficiency virus gag DNA and the cognate gp140 protein before intrarectal challenge with SHIV89.6P-MN. Day-of-challenge sera from animals immunized with mutant N7 Env had significantly higher and broader neutralizing activities than sera from WT Env-immunized animals. Neutralizing activity was observed against SHIV89.6, SHIV89.6P-MN, HIV-1 SF162, and a panel of subtype B primary isolates. Compared to control animals, immunized animals showed significant reduction of plasma viral load and increased survival after challenge, which correlated with prechallenge NtAb titers. These results indicate the potential advantages for glycan modification in vaccine design, although the role of specific glycans requires further examination.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Virol

DOI

EISSN

1098-5514

Publication Date

January 2008

Volume

82

Issue

2

Start / End Page

638 / 651

Location

United States

Related Subject Headings

  • Virology
  • Viral Load
  • Vaccinia virus
  • Vaccines, Synthetic
  • Survival Analysis
  • Simian Acquired Immunodeficiency Syndrome
  • Polysaccharides
  • Neutralization Tests
  • Mutant Proteins
  • Macaca nemestrina
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Li, Y., Cleveland, B., Klots, I., Travis, B., Richardson, B. A., Anderson, D., … Hu, S.-L. (2008). Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol, 82(2), 638–651. https://doi.org/10.1128/JVI.01691-07
Li, Yun, Bradley Cleveland, Igor Klots, Bruce Travis, Barbra A. Richardson, David Anderson, David Montefiori, Patricia Polacino, and Shiu-Lok Hu. “Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.J Virol 82, no. 2 (January 2008): 638–51. https://doi.org/10.1128/JVI.01691-07.
Li Y, Cleveland B, Klots I, Travis B, Richardson BA, Anderson D, et al. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol. 2008 Jan;82(2):638–51.
Li, Yun, et al. “Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.J Virol, vol. 82, no. 2, Jan. 2008, pp. 638–51. Pubmed, doi:10.1128/JVI.01691-07.
Li Y, Cleveland B, Klots I, Travis B, Richardson BA, Anderson D, Montefiori D, Polacino P, Hu S-L. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol. 2008 Jan;82(2):638–651.

Published In

J Virol

DOI

EISSN

1098-5514

Publication Date

January 2008

Volume

82

Issue

2

Start / End Page

638 / 651

Location

United States

Related Subject Headings

  • Virology
  • Viral Load
  • Vaccinia virus
  • Vaccines, Synthetic
  • Survival Analysis
  • Simian Acquired Immunodeficiency Syndrome
  • Polysaccharides
  • Neutralization Tests
  • Mutant Proteins
  • Macaca nemestrina